Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
Altimmune (NASDAQ: ALT), a late clinical-stage biopharmaceutical company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025. The company will host a conference call and webcast at 8:30 am E.T. on the same day, during which management will discuss the financial performance and provide a business update.
Investors can access the webcast through Altimmune's Investor Relations website, and participants wishing to join the call can register to receive dial-in information. A replay of the call will be available on the company's website for up to three months following the event.
Altimmune (NASDAQ: ALT), un'azienda biofarmaceutica in fase clinica avanzata, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 13 maggio 2025. La società terrà una conference call e una webcast alle 8:30 am E.T. dello stesso giorno, durante le quali il management discuterà le performance finanziarie e fornirà un aggiornamento sul business.
Gli investitori potranno accedere alla webcast tramite il sito web delle Relazioni con gli Investitori di Altimmune, e i partecipanti interessati a unirsi alla chiamata potranno registrarsi per ricevere le informazioni per il collegamento. Una registrazione della chiamata sarà disponibile sul sito aziendale per un periodo fino a tre mesi dopo l'evento.
Altimmune (NASDAQ: ALT), una compañía biofarmacéutica en etapa clínica avanzada, ha programado el anuncio de resultados financieros del primer trimestre de 2025 para el martes 13 de mayo de 2025. La empresa realizará una llamada conferencia y una transmisión en vivo a las 8:30 am E.T. del mismo día, durante las cuales la dirección discutirá el desempeño financiero y proporcionará una actualización del negocio.
Los inversores pueden acceder a la transmisión en vivo a través del sitio web de Relaciones con Inversores de Altimmune, y los participantes que deseen unirse a la llamada pueden registrarse para recibir la información de acceso. Una repetición de la llamada estará disponible en el sitio web de la empresa durante hasta tres meses después del evento.
Altimmune (NASDAQ: ALT)는 후기 임상 단계의 바이오제약 회사로서 2025년 1분기 재무 결과 발표를 2025년 5월 13일 화요일로 예정했습니다. 회사는 같은 날 오전 8:30am E.T.에 컨퍼런스 콜과 웹캐스트를 진행하며, 경영진이 재무 성과를 논의하고 사업 현황을 업데이트할 예정입니다.
투자자들은 Altimmune의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 콜에 참여를 원할 경우 등록 후 전화 접속 정보를 받을 수 있습니다. 콜 녹음은 행사 후 최대 3개월 동안 회사 웹사이트에서 다시 들을 수 있습니다.
Altimmune (NASDAQ : ALT), une société biopharmaceutique en phase clinique avancée, a programmé l'annonce des résultats financiers du premier trimestre 2025 pour le mardi 13 mai 2025. La société organisera une conférence téléphonique et une webdiffusion à 8h30 (heure de l'Est) le même jour, au cours desquelles la direction discutera des performances financières et fournira une mise à jour sur les activités.
Les investisseurs peuvent accéder à la webdiffusion via le site des relations investisseurs d'Altimmune, et les participants souhaitant rejoindre l'appel peuvent s'inscrire pour recevoir les informations de connexion. Un replay de l'appel sera disponible sur le site de la société pendant une durée allant jusqu'à trois mois après l'événement.
Altimmune (NASDAQ: ALT), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 13. Mai 2025, geplant. Das Unternehmen wird am selben Tag um 8:30 Uhr E.T. eine Telefonkonferenz und Webcast veranstalten, bei der das Management die finanzielle Leistung besprechen und ein Geschäftsupdate geben wird.
Investoren können über die Investor-Relations-Website von Altimmune auf den Webcast zugreifen, und Teilnehmer, die dem Anruf beitreten möchten, können sich registrieren, um die Einwahlinformationen zu erhalten. Eine Aufzeichnung des Anrufs wird bis zu drei Monate nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 13, 2025.
Altimmune management will host a conference call at 8:30 am E.T. on May 13 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH, alcohol use disorder as well as alcohol related liver disease. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jake Robison
Inizio Evoke, Biotech
Phone: 619-849-5383
Jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) report Q1 2025 earnings?
How can investors access Altimmune's Q1 2025 earnings call?
Will there be a replay available of Altimmune's Q1 2025 earnings call?
What type of company is Altimmune (ALT)?
